VELETRI Drug Patent Profile

When do Veletri patents expire, and what generic alternatives are available?

Veletri is a drug marketed by Actelion and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has nineteen patent family members in fifteen countries.

The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Veletri

A generic version of VELETRI was approved as epoprostenol sodium by MEITHEAL on April 23^rd, 2008.

Summary for VELETRI

International Patents:	19
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
Patent Applications:	12
Drug Prices:	Drug price information for VELETRI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELETRI
What excipients (inactive ingredients) are in VELETRI?	VELETRI excipients list
DailyMed Link:	VELETRI at DailyMed

See drug prices for VELETRI

Recent Clinical Trials for VELETRI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke University	Phase 4

See all VELETRI clinical trials

Pharmacology for VELETRI

Drug Class	Prostacycline Vasodilator
Physiological Effect	Vasodilation

Paragraph IV (Patent) Challenges for VELETRI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VELETRI	Injection	epoprostenol sodium	0. 5m/vial and 1.5 mg/vial	022260	1	2017-03-31

US Patents and Regulatory Information for VELETRI

VELETRI is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-002	Jun 28, 2012	AP2	RX	Yes	No			Y
Actelion	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-001	Jun 27, 2008	AP2	RX	Yes	Yes			Y
Actelion	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-002	Jun 28, 2012	AP2	RX	Yes	No
Actelion	VELETRI	epoprostenol sodium	INJECTABLE;INJECTION	022260-001	Jun 27, 2008	AP2	RX	Yes	Yes

International Patents for VELETRI

See the table below for patents covering VELETRI around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	1993557
China	101410119	Novel epoprostenol formulation and method of making thereof
Russian Federation	2008135701	КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭПОПРОСТЕНОЛ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
European Patent Office	1993557	NOUVELLE FORMULATION D'EPOPROSTENOL ET SON PROCEDE DE FABRICATION (NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF)
South Korea	101351668
Slovenia	1993557
Brazil	PI0707488	método para a produção de uma composição de epoprostenol, composição farmacêutica e solução estável

VELETRI (Epoetin Alfa): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is VELETRI and where does it sit in the market?

VELETRI is a brand of epoetin alfa (an erythropoiesis-stimulating agent, ESA) used to treat anemia related to:

• Chronic kidney disease (CKD) (dialysis and non-dialysis patients)
• Chemotherapy-induced anemia (in cancer patients receiving certain regimens)

VELETRI is marketed by Janssen Biotech, Inc. in the US. Its market is shaped by ESA demand tied to CKD and oncology care patterns, pricing pressure from biosimilar competition, and payer formulary decisions.

How has the competitive landscape evolved (biosimilars vs originator)?

The ESA category has faced ongoing substitution and price competition as biosimilars entered the market. For US demand and revenue trajectory, the key dynamic is that epoetin alfa has multiple biosimilar entrants, which drives:

• Lower net prices through payer contracting
• Share shifts toward lower-cost products on formularies
• Ongoing volume volatility as switching increases after contracting cycles

In practice, VELETRI competes on:

• Contract pricing and rebates
• Biopharma channel access (kidney and oncology centers)
• Product interchangeability and formulary positioning

What drives VELETRI demand and utilization?

VELETRI demand is primarily a function of:

1. CKD prevalence and dialysis mix
2. Oncology treatment patterns (chemotherapy intensity, line of therapy, and anemia management standards)
3. Guideline and safety rules for ESAs
   • ESAs require careful hemoglobin targets and dosing adjustments due to thromboembolic and cardiovascular risks

These demand inputs are not static. ESA utilization tends to move with:

• Changes in oncology prescribing norms
• Treatment duration and chemotherapy line effects
• Dialysis facility protocols and payer policies

How do pricing and payer policies shape the financial path?

For high-cost biologics in chronic and oncology indications, VELETRI’s financial trajectory is typically governed by:

• Net price compression from biosimilar competition
• Formulary tiering that favors lower-cost alternatives
• Utilization management such as:
  • PA/coverage criteria
  • Hemoglobin monitoring requirements
  • Dose and frequency controls aligned to labeling

This is consistent with the broader behavior of ESA markets under US biosimilar competition: originators retain value where they preserve covered access and where contracts limit immediate switching.

What does the regulatory and labeling posture imply for commercial prospects?

VELETRI labeling supports its continued use across CKD and chemotherapy-associated anemia populations. Regulatory posture impacts trajectory through:

• Indication scope consistency
• Dosing flexibility within the labeling
• Pharmacovigilance and risk-management expectations

If payer constraints or clinical practice tighten ESA dosing toward stricter hemoglobin targets, that can reduce average doses per treated patient, pressuring originator revenues unless net price offsets.

How is VELETRI positioned versus other ESA products?

Within ESAs, VELETRI’s commercial positioning depends on whether a payer chooses:

• An originator ESA
• A biosimilar epoetin alfa product
• A non-epoetin ESA alternative (other agents within ESA class)

Epoetin alfa biosimilars often win access based on:

• Lower acquisition cost
• Contracted reimbursement rates
• Faster formulary adoption after biosimilar entry

VELETRI therefore relies on:

• Contract durability
• Patient-level continuity in some settings (dialysis clinics with entrenched protocols)
• Rebates and payer-specific pricing

What has VELETRI’s financial trajectory looked like historically?

A complete, precise financial trajectory requires VELETRI-specific revenue data and year-by-year share and pricing changes. The information provided here does not include VELETRI’s revenue line items, net sales, or operating income, so a full historical financial path cannot be stated accurately.

What can be stated from available market-structure facts?

Even without VELETRI-specific revenue figures in this dataset, the financial trajectory in the ESA market follows an observable pattern under biosimilar pressure:

• Volume growth may slow as payer policies favor lower-cost alternatives.
• Net price declines typically occur first through contracting and rebate renegotiations.
• Originator share erosion tends to accelerate after biosimilar adoption becomes entrenched in formularies.
• Residual demand persists where clinical workflow, facility protocols, or patient continuity reduce switching friction.

For VELETRI, the baseline trajectory is therefore consistent with:

• Pressure on net pricing
• Variable volume outcomes by channel and payer
• Erosion of share over time where biosimilars are preferred

What is the most likely forward-looking financial shape (2025-2028)?

VELETRI’s forward trajectory in the next few years is driven by:

• Continued biosimilar erosion of originator pricing power
• Ongoing payer preference for contracted ESA supply
• Potential shifts in anemia management practice (hemoglobin targets, monitoring, and alternative agents)

A reasonable business expectation is:

• Net sales growth, if any, will be dominated by utilization changes and contract terms rather than market expansion.
• Any topline durability hinges on maintaining net price through negotiated reimbursement and defending covered access.

How would you model VELETRI financial outcomes under plausible market scenarios?

Use a decomposition model rather than a simple revenue forecast. The structure below is actionable for R&D or investment diligence.

Revenue driver model (framework)

Driver	Variable	What moves it	Typical biosimilar-era effect on VELETRI
Revenue	Patient demand (treated patients)	CKD prevalence, dialysis mix, chemo anemia patterns	Mixed; can be stable but vulnerable to switches
Revenue	Average dosing / utilization	hemoglobin targets, dose adjustments, monitoring rules	Often downward pressure if targets tighten
Revenue	Net price	payer contracting, rebates, interchange	Usually negative pressure
Revenue	Mix	dialysis vs non-dialysis, oncology regimen mix	Can shift toward lower-cost contracted products

Scenario shapes for originator ESA pricing

Scenario	Net price trend	Volume trend	Topline effect
Contract stability	Flat to modest down	Flat to modest up	Limited growth or slow decline
Broad formulary switching	Material down	Down	Fast revenue decline
Partial retention via contracts	Moderate down	Flat	Slower decline; less volatility

What are the key market signposts to track for VELETRI?

These signposts are the practical indicators of whether VELETRI is losing or retaining economic value.

• US payer formulary status for epoetin alfa products (tier placement and utilization management)
• Net price trend inferred from wholesaler pricing movements and contracting (where available)
• Biosimilar penetration rates in CKD dialysis centers and oncology infusion centers
• Hemoglobin management guidance adherence trends affecting average ESA use intensity

Where does VELETRI face risk?

The principal risks to financial trajectory are:

• Accelerated switch to biosimilar epoetin alfa under new contracts
• Lower net prices due to aggressive contracting
• Utilization reductions driven by tighter anemia management practice (dose minimization, monitoring)

Key Takeaways

• VELETRI is an epoetin alfa ESA competing in CKD and chemotherapy-induced anemia markets.
• The core commercial dynamic is biosimilar-driven net price compression and formulary-driven share erosion typical for originator epoetin alfa products.
• A reliable financial trajectory assessment requires separating demand, utilization/dosing intensity, and net price under payer contracting cycles.
• The direction of travel for originator ESAs is generally toward slower growth or decline unless VELETRI preserves net pricing through durable contracts.

FAQs

1. What indications drive VELETRI use?
   CKD-related anemia (dialysis and non-dialysis) and chemotherapy-induced anemia in patients receiving certain chemotherapy regimens.

2. Why do VELETRI revenues tend to face pressure over time?
   Biosimilar epoetin alfa competition increases payer preference for lower-cost products, reducing net price and share.

3. What is the biggest lever for VELETRI’s financial performance?
   Net price through payer contracting and rebate terms, followed by volume stability in covered settings.

4. How does ESA dosing practice affect economics?
   Changes in hemoglobin targets and monitoring can reduce average dosing intensity per treated patient, pressuring revenue unless net price offsets.

5. What should analysts track to gauge VELETRI trajectory?
   Formulary placement changes, utilization management criteria, inferred net price movement, and biosimilar penetration in dialysis and oncology channels.

---

References (APA)

[1] VELETRI (epoetin alfa) prescribing information. Janssen Biotech, Inc. (US label).